Evidence map›Paper›PMID 42063338›Full record

ArticleJournal of medicinal chemistry2026

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Stephanie A Vogt, Alexander J Lander, Karl Herbine, Ekaterina Umnyakova, Jannes Felsch, Roman Aschwanden, Sarah E Hughes, Oliver Schwardt, Markus A Lill, Martin Smieško and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stephanie A VogtDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0009-0000-5938-2558
Alexander J LanderDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-0733-6597
Karl HerbineDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 422 Curie Blvd, Philadelphia 19104, Pennsylvania, United States.ORCID 0000-0002-1973-7817
Ekaterina UmnyakovaDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Jannes FelschDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Roman AschwandenDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Sarah E HughesDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 422 Curie Blvd, Philadelphia 19104, Pennsylvania, United States.
Oliver SchwardtDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Markus A LillDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-3023-5188
Martin SmieškoDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-2758-2680
John D LambrisDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 422 Curie Blvd, Philadelphia 19104, Pennsylvania, United States.ORCID 0000-0002-9370-5776
Christina LamersDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-0962-8171
Daniel RicklinDepartment of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0001-6140-0233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compstatin-class macrocyclic peptides have emerged as therapeutic complement modulators, with a PEGylated compstatin derivative being approved and sequence-optimized analogs with enhanced PK/PD properties showing clinical promise. By extending structure-activity relationship studies of compstatin, we identified a modification (V3I) that enhances the target affinity up to 30-fold. Analog Cp01-V3I represents the most potent proteinogenic compstatin (

Indexed as

Complement Inactivating AgentsPeptides, CyclicHumansStructure-Activity RelationshipComplement Inactivating AgentscompstatinPeptides, Cyclic

Identifiers

PMID42063338
PMCPMC13181761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.